SCHEMBL21553098

SCHEMBL21553098

O=C(O)N1CCN(c2nc(CCCO)cn(-c3ccc(F)cc3)c2=O)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.38
MEN1 O00255 1/20 0.37
PARP1 P09874 1/20 0.37
KMT2A Q03164 1/20 0.37
PARP2 Q9UGN5 1/20 0.37
POLB P06746 2/20 0.37
ALDH1A1 P00352 4/20 0.37
LMNA P02545 4/20 0.36
MAPT P10636 3/20 0.36
GRM5 P41594 1/20 0.36
TSHR P16473 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21564491 0.87 MEN1 (0.42) MEN1KMT2AALDH1A1LMNASMN1; SMN2
SCHEMBL21553144 0.87 NPC1 (0.39) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL21553057 0.86 LMNA (0.38) GFERMEN1PARP1KMT2APARP2
SCHEMBL21564509 0.85 GRIA1 (0.42) MEN1KMT2APOLBALDH1A1LMNA
SCHEMBL21552985 0.85 DGAT1 (0.36) ALDH1A1MAPTTSHRKDM4EHSD17B10
SCHEMBL21564469 0.85 ALDH1A1 (0.43) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL21564667 0.84 ALDH1A1 (0.33) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL21553047 0.84 CMA1 (0.34)
SCHEMBL21552986 0.83 MAPK1 (0.40) ALDH1A1MAPTTSHRSMN1; SMN2GAA
SCHEMBL21552853 0.83 GABRA2 (0.41) GFERMEN1KMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790867-B1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2024-03-27 EP disclosed
US-11932629-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
EP-3790867-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2021-03-17 EP disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932629-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A GFER 3534/4885MEN1 3684/4885PARP1 1042/4885
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A GFER 3534/4885MEN1 3684/4885PARP1 1042/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A GFER 3360/4885MEN1 3213/4885PARP1 763/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A GFER 3534/4885MEN1 3684/4885PARP1 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.